SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma soars on the buzz of plan to increase product filings for US

13 Oct 2016 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 691.35, up by 19.45 points or 2.89% from its previous closing of Rs. 671.90 on the BSE.

The scrip opened at Rs. 670.00 and has touched a high and low of Rs. 691.35 and Rs. 670.00 respectively. So far 9160 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 733.00 on 15-Oct-2015 and a 52 week low of Rs. 514.35 on 05-Feb-2016.

Last one week high and low of the scrip stood at Rs. 699.50 and Rs. 655.00 respectively. The current market cap of the company is Rs. 13010.43 crore.

The promoters holding in the company stood at 74.35%, while institutions and non-institutions held 13.79% and 11.86% respectively.

Alembic Pharmaceuticals is reportedly planning to increase its annual product filings for regulated markets from 7 now to 30 within two years. The Vadodara-based company has increased the number of its projects for product development from 40 in 2013-14 to 200 now. The projects are largely to develop products in injectables and dermatology. These include its own, partnered, and in-licensed products.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

 

Alembic Pharma Share Price

759.00 -25.95 (-3.31%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×